Lorlatinib Market Summary

Key Factors Driving Lorlatinib Growth

1. Exceptional long-term efficacy in first-line ALK-positive NSCLC: The Phase III CROWN trial has become the strongest clinical driver for LORBRENA. After approximately five years of follow-up, median PFS remained not reached with lorlatinib versus 9.1 months with crizotinib, corresponding to an 81% reduction in the risk of progression or death (HR 0.19). The estimated 5-year PFS was 60% versus 8%, respectively. These unusually durable results reinforce lorlatinib's positioning as a preferred first-line ALK inhibitor.

2. Outstanding CNS activity differentiates lorlatinib: CNS penetration is particularly important in ALK-positive NSCLC because brain metastases are common. In the five-year CROWN analysis, lorlatinib reduced the risk of intracranial progression by approximately 94% versus crizotinib. Among patients with baseline brain metastases, the median time to intracranial progression was not reached with lorlatinib versus 6.0 months with crizotinib, with a hazard ratio of approximately 0.06.

3. Increasing first-line market share is directly translating into sales growth: Pfizer's latest annual filing provides particularly strong evidence that commercial expansion is being driven by greater patient share in first-line ALK-positive metastatic NSCLC. In 2025, Lorbrena worldwide revenue reached $1.023 billion, up 40% operationally from $731 million in 2024. Pfizer specifically attributed this growth to increased patient share in the first-line setting in the U.S., China and certain other international markets.

4. Rapid transition from a niche second-line product to a blockbuster: Lorbrena's commercial trajectory has accelerated substantially since first-line use became established. Pfizer reported sales of approximately $343 million in 2022, $539 million in 2023, $731 million in 2024, and $1.023 billion in 2025. Thus, sales nearly tripled between 2022 and 2025, while 2025 marked the first year above the $1 billion threshold.

5. Growing penetration in China and international markets provides another major growth lever: Pfizer's 2025 results show that international sales increased particularly strongly, reaching $616 million, up 44% operationally, compared with $424 million in 2024. Pfizer specifically cited increased first-line patient share in China and other international markets as a growth driver. This is important because ALK-positive NSCLC represents a particularly relevant biomarker-defined population in Asian lung-cancer populations.

Lorlatinib Recent Developments

In May 2026, Pfizer Inc. announced unprecedented seven-year follow-up results from the Phase III CROWN trial evaluating LORBRENA (lorlatinib, a third-generation ALK inhibitor, available in Europe under the brand name LORVIQUA) versus XALKORI (crizotinib) in people with previously untreated, anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC).

At seven years, patients treated with LORBRENA had a 55% likelihood of remaining alive without disease progression (95% Confidence Interval [CI], 46-63) compared to 3% (95% CI, 1-8) in the XALKORI treatment arm. Further, an updated analysis at seven years of median follow-up showed that investigator-assessed median progression-free survival (PFS) had not been reached with LORBRENA, with an estimated Hazard Ratio (HR) of 0.19 (95% CI, 0.13-0.26), representing an 81% reduction in the risk of disease progression or death compared to XALKORI.

“Lorlatinib Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Lorlatinib for approved indication like Non-small cell lung cancer in the 7MM. A detailed picture of Lorlatinib’s existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Lorlatinib for approved indications. The Lorlatinib market report provides insights about Lorlatinib’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Lorlatinib performance, future market assessments inclusive of the Lorlatinib market forecast analysis for approved indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Lorlatinib sales forecasts, along with factors driving its market.

Lorlatinib Drug Summary

Lorlatinib is an orally administered, third-generation tyrosine kinase inhibitor developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer (NSCLC). It is a potent, selective ALK and ROS1 inhibitor designed to overcome a broad range of resistance mutations that can emerge during treatment with earlier-generation ALK inhibitors, and it has strong penetration across the blood–brain barrier, providing activity against central nervous system metastases. LORBRENA is approved as a first-line treatment for adult patients with locally advanced or metastatic ALK-positive NSCLC and is administered orally once daily, with treatment generally continued until disease progression or unacceptable toxicity. Common adverse reactions include hypercholesterolemia, hypertriglyceridemia, edema, weight gain, peripheral neuropathy, cognitive and mood effects, and fatigue, while important risks include central nervous system effects, hyperlipidemia, atrioventricular block, hypertension, and serious interactions with CYP3A inducers. The report provides Lorlatinib’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Lorlatinib Market Report

The report provides insights into:

• A comprehensive product overview including the Lorlatinib MoA, description, dosage and administration, research and development activities in approved indication like Non-small cell lung cancer.
• Elaborated details on Lorlatinib regulatory milestones and other development activities have been provided in Lorlatinib market report.
• The report also highlights Lorlatinib‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
• The Lorlatinib market report also covers the patents information, generic entry and impact on cost cut.
• The Lorlatinib market report contains current and forecasted Lorlatinib sales for approved indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Lorlatinib market report also features the SWOT analysis with analyst views for Lorlatinib in approved indications.

Methodology

The Lorlatinib market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Lorlatinib Analytical Perspective by DelveInsight

• In-depth Lorlatinib Market Assessment

This Lorlatinib sales market forecast report provides a detailed market assessment of Lorlatinib for approved indication like Non-small cell lung cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Lorlatinib sales data uptil 2034.

• Lorlatinib Clinical Assessment

The Lorlatinib market report provides the clinical trials information of Lorlatinib for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.

Lorlatinib Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Lorlatinib Market Potential & Revenue Forecast

• Projected market size for the Lorlatinib and its key indications
• Estimated Lorlatinib sales potential (Lorlatinib peak sales forecasts)
• Lorlatinib Pricing strategies and reimbursement landscape

Lorlatinib Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Lorlatinib Market positioning compared to existing treatments
• Lorlatinib Strengths & weaknesses relative to competitors

Lorlatinib Regulatory & Commercial Milestones

• Lorlatinib Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Lorlatinib Clinical Differentiation

• Lorlatinib Efficacy & safety advantages over existing drugs
• Lorlatinib Unique selling points

Lorlatinib Market Report Highlights

• In the coming years, the Lorlatinib market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Lorlatinib companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Lorlatinib’s dominance.
• Other emerging products for Non-small cell lung cancer are expected to give tough market competition to Lorlatinib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Lorlatinib in approved indications.
• Analyse Lorlatinib cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Lorlatinib sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Lorlatinib in approved indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Lorlatinib? How strong is Lorlatinib’s clinical and commercial performance?
• What is Lorlatinib’s clinical trial status in each individual indications such as Non-small cell lung cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Lorlatinib Manufacturers?
• What are the key designations that have been granted to Lorlatinib for approved indications? How are they going to impact Lorlatinib’s penetration in various geographies?
• What is the current and forecasted Lorlatinib market scenario for approved indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Lorlatinib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Lorlatinib for approved indications?
• Which are the late-stage emerging therapies under development for the treatment of approved indications?
• How cost-effective is Lorlatinib? What is the duration of therapy and what are the geographical variations in cost per patient?